Synthesis and Molecular Dynamic Simulation of Novel Cationic and Non-cationic Pyrimidine Derivatives as Potential G-quadruplex-ligands


Cite item

Full Text

Abstract

Background:Drug resistance has been a problem in cancer chemotherapy, which often causes shortterm effectiveness. Further, the literature indicates that telomere G-quadruplex could be a promising anti-cancer target.

Objective:We synthesized and characterized two new pyrimidine derivatives as ligands for G-quadruplex DNA.

Methods:The interaction of novel non-cationic and cationic pyrimidine derivatives (3a, b) with G-quadruplex DNA (1k8p and 3qsc) was explored by circular dichroism (CD) and ultraviolet-visible spectroscopy and polyacrylamide gel electrophoresis (PAGE) methods. The antiproliferative activity of desired compounds was evaluated by the MTT assay. Apoptosis induction was assessed by Propidium iodide (P.I.) staining and flow cytometry. Computational molecular modeling (CMM) and molecular dynamics simulation (MD) were studied on the complexes of 1k8p and 3qsc with the compounds. The van der Waals, electrostatic, polar solvation, solventaccessible surface area (SASA), and binding energies were calculated and analyzed.

Results:The experimental results confirmed that both compounds 3a and 3b interacted with 1k8p and 3qsc and exerted cytotoxic and proapoptotic effects on cancer cells. The number of hydrogen bonds and the RMSD values increased in the presence of the ligands, indicating stronger binding and suggesting increased structural dynamics. The electrostatic contribution to binding energy was higher for the cationic pyrimidine 3b, indicating more negative binding energies.

Conclusion:Both experimental and MD results confirmed that 3b was more prone to form a complex with DNA G-quadruplex (1k8p and 3qsc), inhibit cell growth, and induce apoptosis, compared to the non-cationic pyrimidine 3a.

About the authors

Hoda Atapour-Mashhad

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Mohammad Soukhtanloo

Department of Clinical Biochemistry, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Shiva Golmohammadzadeh

Nanotechnology Research Center, Pharmaceutical Technology Institute,, Mashhad University of Medical Sciences

Email: info@benthamscience.net

Jamshidkhan Chamani

Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University

Email: info@benthamscience.net

Mojgan Nejabat

Department of Medicinal Chemistry, School of Pharmacy,, Mashhad University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

Farzin Hadizadeh

Biotechnology Research Center, Pharmaceutical Technology Institute,, Mashhad University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Hurley, L.H.; Wheelhouse, R.T.; Sun, D.; Kerwin, S.M.; Salazar, M.; Fedoroff, O.Y.; Han, F.X.; Han, H.; Izbicka, E.; Von Hoff, D.D. G-quadruplexes as targets for drug design. Pharmacol. Ther., 2000, 85(3), 141-158. doi: 10.1016/S0163-7258(99)00068-6 PMID: 10739869
  2. Shay, J.W.; Keith, W.N. Targeting telomerase for cancer therapeutics. Br. J. Cancer, 2008, 98(4), 677-683. doi: 10.1038/sj.bjc.6604209 PMID: 18231105
  3. Guterres, A.N.; Villanueva, J. Targeting telomerase for cancer therapy. Oncogene, 2020, 39(36), 5811-5824. doi: 10.1038/s41388-020-01405-w PMID: 32733068
  4. Neidle, S.; Parkinson, G. Telomere maintenance as a target for anticancer drug discovery. Nat. Rev. Drug Discov., 2002, 1(5), 383-393. doi: 10.1038/nrd793 PMID: 12120414
  5. Kerwin, S. G-Quadruplex DNA as a target for drug design. Curr. Pharm. Des., 2000, 6(4), 441-471. doi: 10.2174/1381612003400849 PMID: 10788591
  6. Zeng, X.; Hernandez-Sanchez, W.; Xu, M.; Whited, T.L.; Baus, D.; Zhang, J.; Berdis, A.J.; Taylor, D.J. Administration of a nucleoside analog promotes cancer cell death in a telomerase-dependent manner. Cell Rep., 2018, 23(10), 3031-3041. doi: 10.1016/j.celrep.2018.05.020 PMID: 29874588
  7. Chilton, W.; O’Brien, B.; Charchar, F. Telomeres, aging and exercise: Guilty by association? Int. J. Mol. Sci., 2017, 18(12), 2573. doi: 10.3390/ijms18122573 PMID: 29186077
  8. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.C.; Coviello, G.M.; Wright, W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science, 1994, 266(5193), 2011-2015. doi: 10.1126/science.7605428 PMID: 7605428
  9. Zahler, A.M.; Williamson, J.R.; Cech, T.R.; Prescott, D.M. Inhibition of telomerase by G-quartet DMA structures. Nature, 1991, 350(6320), 718-720. doi: 10.1038/350718a0 PMID: 2023635
  10. Hirt, B.V.; Wattis, J.A.D.; Preston, S.P. Modelling the regulation of telomere length: The effects of telomerase and G-quadruplex stabilising drugs. J. Math. Biol., 2014, 68(6), 1521-1552. doi: 10.1007/s00285-013-0678-2 PMID: 23620229
  11. Paeschke, K.; Simonsson, T.; Postberg, J.; Rhodes, D.; Lipps, H.J. Telomere end-binding proteins control the formation of G-quadruplex DNA structures in vivo. Nat. Struct. Mol. Biol., 2005, 12(10), 847-854. doi: 10.1038/nsmb982 PMID: 16142245
  12. Moye, A.L.; Porter, K.C.; Cohen, S.B.; Phan, T.; Zyner, K.G.; Sasaki, N.; Lovrecz, G.O.; Beck, J.L.; Bryan, T.M. Telomeric G-quadruplexes are a substrate and site of localization for human telomerase. Nat. Commun., 2015, 6(1), 7643. doi: 10.1038/ncomms8643 PMID: 26158869
  13. Paudel, B.P.; Moye, A.L.; Abou Assi, H.; El-Khoury, R.; Cohen, S.B.; Holien, J.K.; Birrento, M.L.; Samosorn, S.; Intharapichai, K.; Tomlinson, C.G.; Teulade-Fichou, M.P.; González, C.; Beck, J.L.; Damha, M.J.; van Oijen, A.M.; Bryan, T.M. A mechanism for the extension and unfolding of parallel telomeric G-quadruplexes by human telomerase at single-molecule resolution. eLife, 2020, 9, e56428. doi: 10.7554/eLife.56428 PMID: 32723475
  14. Bryan, T.M. G-quadruplexes at telomeres: Friend or foe? Molecules, 2020, 25(16), 3686. doi: 10.3390/molecules25163686 PMID: 32823549
  15. Maiti, S.; Saha, P.; Das, T.; Bessi, I.; Schwalbe, H.; Dash, J. Human telomeric G-quadruplex selective fluoro-isoquinolines induce apoptosis in cancer cells. Bioconjug. Chem., 2018, 29(4), 1141-1154. doi: 10.1021/acs.bioconjchem.7b00781 PMID: 29433312
  16. Pennarun, G.; Granotier, C.; Gauthier, L.R.; Gomez, D.; Hoffschir, F.; Mandine, E.; Riou, J.F.; Mergny, J.L.; Mailliet, P.; Boussin, F.D. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene, 2005, 24(18), 2917-2928. doi: 10.1038/sj.onc.1208468 PMID: 15735722
  17. Burge, S.; Parkinson, G.N.; Hazel, P.; Todd, A.K.; Neidle, S. Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res., 2006, 34(19), 5402-5415. doi: 10.1093/nar/gkl655 PMID: 17012276
  18. Phatak, P.; Cookson, J.C.; Dai, F.; Smith, V.; Gartenhaus, R.B.; Stevens, M F G.; Burger, A.M. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br. J. Cancer, 2007, 96(8), 1223-1233. doi: 10.1038/sj.bjc.6603691 PMID: 17406367
  19. Jenkins, T. Targeting multi-stranded DNA structures. Curr. Med. Chem., 2000, 7(1), 99-115. doi: 10.2174/0929867003375551 PMID: 10637359
  20. Sun, D.; Hurley, L.H. Targeting telomeres and telomerase. Methods Enzymol., 2001, 340, 573-592. doi: 10.1016/S0076-6879(01)40443-5 PMID: 11494871
  21. Raymond, E.; Sun, D.; Chen, S.F.; Windle, B.; Von Hoff, D.D. Agents that target telomerase and telomeres. Curr. Opin. Biotechnol., 1996, 7(6), 583-591. doi: 10.1016/S0958-1669(96)80068-1 PMID: 8939642
  22. Kelland, L.R. Telomerase: Biology and phase I trials. Lancet Oncol., 2001, 2(2), 95-102. doi: 10.1016/S1470-2045(00)00226-6 PMID: 11905801
  23. Bearss, D.J.; Hurley, L.H.; Von Hoff, D.D. Telomere maintenance mechanisms as a target for drug development. Oncogene, 2000, 19(56), 6632-6641. doi: 10.1038/sj.onc.1204092 PMID: 11426649
  24. Campbell, N.H.; Parkinson, G.N.; Reszka, A.P.; Neidle, S. Structural basis of DNA quadruplex recognition by an acridine drug. J. Am. Chem. Soc., 2008, 130(21), 6722-6724. doi: 10.1021/ja8016973 PMID: 18457389
  25. Sun, D.; Thompson, B.; Cathers, B.E.; Salazar, M.; Kerwin, S.M.; Trent, J.O.; Jenkins, T.C.; Neidle, S.; Hurley, L.H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem., 1997, 40(14), 2113-2116. doi: 10.1021/jm970199z PMID: 9216827
  26. Riou, J.F.; Guittat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitgenet, O.; Mégnin-Chanet, F.; Hélène, C.; Mergny, J.L. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA, 2002, 99(5), 2672-2677. doi: 10.1073/pnas.052698099 PMID: 11854467
  27. Fletcher, T.M. Telomerase: A potential therapeutic target for cancer. Expert Opin. Ther. Targets, 2005, 9(3), 457-469. doi: 10.1517/14728222.9.3.457 PMID: 15948667
  28. Allsopp, R.C.; Harley, C.B. Evidence for a critical telomere length in senescent human fibroblasts. Exp. Cell Res., 1995, 219(1), 130-136. doi: 10.1006/excr.1995.1213 PMID: 7628529
  29. Neidle, S. Human telomeric G‐quadruplex: The current status of telomeric G‐quadruplexes as therapeutic targets in human cancer. FEBS J., 2010, 277(5), 1118-1125. doi: 10.1111/j.1742-4658.2009.07463.x PMID: 19951354
  30. Mergny, J.L.; Hélène, C. G-quadruplex DNA: A target for drug design. Nat. Med., 1998, 4(12), 1366-1367. doi: 10.1038/3949 PMID: 9846570
  31. Han, H.; Hurley, L.H. G-quadruplex DNA: A potential target for anti-cancer drug design. Trends Pharmacol. Sci., 2000, 21(4), 136-142. doi: 10.1016/S0165-6147(00)01457-7 PMID: 10740289
  32. Kosiol, N.; Juranek, S.; Brossart, P.; Heine, A.; Paeschke, K. G-quadruplexes: A promising target for cancer therapy. Mol. Cancer, 2021, 20(1), 40. doi: 10.1186/s12943-021-01328-4 PMID: 33632214
  33. Ruggiero, E.; Richter, S.N. G-quadruplexes and G-quadruplex ligands: Targets and tools in antiviral therapy. Nucleic Acids Res., 2018, 46(7), 3270-3283. doi: 10.1093/nar/gky187 PMID: 29554280
  34. Tian, T.; Chen, Y.Q.; Wang, S.R.; Zhou, X. G-Quadruplex: A regulator of gene expression and its chemical targeting. Chem, 2018, 4(6), 1314-1344. doi: 10.1016/j.chempr.2018.02.014
  35. Santos, T.; Salgado, G.F.; Cabrita, E.J.; Cruz, C. G-quadruplexes and their ligands: Biophysical methods to unravel G-quadruplex/ligand interactions. Pharmaceuticals, 2021, 14(8), 769. doi: 10.3390/ph14080769 PMID: 34451866
  36. Andreeva, D.V.; Tikhomirov, A.S.; Shchekotikhin, A.E. Ligands of G-quadruplex nucleic acids. Russ. Chem. Rev., 2021, 90(1), 1-38. doi: 10.1070/RCR4968
  37. Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Nakajima, A.; Shimamoto, T.; Ohyashiki, J.H.; Ohyashiki, K. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways. Oncogene, 2003, 22(34), 5338-5347. doi: 10.1038/sj.onc.1206833 PMID: 12917635
  38. Sanchez-Martin, V.; Soriano, M.; Garcia-Salcedo, J.A. Quadruplex ligands in cancer therapy. Cancers (Basel), 2021, 13(13), 3156. doi: 10.3390/cancers13133156 PMID: 34202648
  39. Wheelhouse, R.T.; Sun, D.; Han, H.; Han, F.X.; Hurley, L.H. Cationic porphyrins as telomerase inhibitors: The interaction of tetra-(N-methyl-4-pyridyl) porphine with quadruplex DNA. J. Am. Chem. Soc., 1998, 120(13), 3261-3262. doi: 10.1021/ja973792e
  40. Guo, Q.L.; Su, H.F.; Wang, N.; Liao, S.R.; Lu, Y.T.; Ou, T.M.; Tan, J.H.; Li, D.; Huang, Z.S. Synthesis and evaluation of 7-substituted-5,6-dihydrobenzocacridine derivatives as new c-KIT promoter G-quadruplex binding ligands. Eur. J. Med. Chem., 2017, 130, 458-471. doi: 10.1016/j.ejmech.2017.02.051 PMID: 28284084
  41. Seenisamy, J.; Bashyam, S.; Gokhale, V.; Vankayalapati, H.; Sun, D.; Siddiqui-Jain, A.; Streiner, N.; Shin-ya, K.; White, E.; Wilson, W.D.; Hurley, L.H. Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J. Am. Chem. Soc., 2005, 127(9), 2944-2959. doi: 10.1021/ja0444482 PMID: 15740131
  42. Eidinoff, M.L.; Knoll, J.E.; Marano, B.J.; Klein, D. Pyrimidine studies. III. Effect of several compounds with antitumor activity on utilization of precursors for synthesis of nucleic acid pyrimidines. Cancer Res., 1961, 21(10), 1377-1385. PMID: 13889598
  43. Donnini, S.; Monti, M.; Castagnini, C.; Solito, R.; Botta, M.; Schenone, S.; Giachetti, A.; Ziche, M. Pyrazolo–pyrimidine‐derived c‐Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int. J. Cancer, 2007, 120(5), 995-1004. doi: 10.1002/ijc.22410 PMID: 17131343
  44. Murashima, T.; Sakiyama, D.; Miyoshi, D.; Kuriyama, M.; Yamada, T.; Miyazawa, T. Cationic porphyrin induced a telomeric DNA to G-quadruplex form in water. Bioinorg. Chem. Appl., 2008, 2008, 294756.
  45. Che, T.; Wang, Y.Q.; Huang, Z.L.; Tan, J.H.; Huang, Z.S.; Chen, S.B. Natural alkaloids and heterocycles as G-quadruplex ligands and potential anticancer agents. Molecules, 2018, 23(2), 493. doi: 10.3390/molecules23020493 PMID: 29473874
  46. Reznichenko, O.; Leclercq, D.; Franco Pinto, J.; Mouawad, L.; Gabelica, V.; Granzhan, A. Optimization of G‐quadruplex ligands through a SAR study combining parallel synthesis and screening of cationic bis(acylhydrazones). Chemistry, 2023, 29(4), e202202427. doi: 10.1002/chem.202202427 PMID: 36286608
  47. Guianvarc, H.D.; Lavergne, T.; Yatsunyk, L.; Blondel, M. The composition of the jury. Avilable From: https://www.universite-paris-saclay.fr/recherche/doctorat-et-hdr/la-composition-du-jury-0
  48. Cadoni, E.; Magalhães, P.R.; Emídio, R.M.; Mendes, E.; Vítor, J.; Carvalho, J.; Cruz, C.; Victor, B.L.; Paulo, A. New (Iso)quinolinyl-pyridine-2,6-dicarboxamide G-Quadruplex Stabilizers. A Structure-Activity Relationship Study. Pharmaceuticals (Basel), 2021, 14(7), 669. doi: 10.3390/ph14070669 PMID: 34358095
  49. Shaban, N.Z.; Masoud, M.S.; Mawlawi, M.A.; Awad, D.; Sadek, O.M. Effect of some pyrimidine compounds on rat brain monoamine oxidase-B in vitro. J. Physiol. Biochem., 2012, 68(4), 475-484. doi: 10.1007/s13105-012-0160-4 PMID: 22467201
  50. Mahapatra, A.; Prasad, T.; Sharma, T. Pyrimidine: A review on anticancer activity with key emphasis on SAR. Future J. Pharm. Sci., 2021, 7(1), 123. doi: 10.1186/s43094-021-00274-8
  51. Prachayasittikul, S.; Worachartcheewan, A.; Nantasenamat, C.; Chinworrungsee, M.; Sornsongkhram, N.; Ruchirawat, S.; Prachayasittikul, V. Synthesis and structure–activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents. Eur. J. Med. Chem., 2011, 46(2), 738-742. doi: 10.1016/j.ejmech.2010.12.009 PMID: 21216051
  52. Sharma, S.K.; Kumar, P.; Narasimhan, B.; Ramasamy, K.; Mani, V.; Mishra, R.K.; Majeed, A.B.A. Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 6-methyl-4-1-(2-substituted-phenylamino-acetyl)-1H-indol-3-yl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl esters. Eur. J. Med. Chem., 2012, 48, 16-25. doi: 10.1016/j.ejmech.2011.11.028 PMID: 22154835
  53. Taher, A.T.; Helwa, A.A. Novel pyrimidinone derivatives: Synthesis, antitumor and antimicrobial evaluation. Chem. Pharm. Bull. (Tokyo), 2012, 60(4), 521-530. doi: 10.1248/cpb.60.521 PMID: 22466736
  54. Taher, A.T.; Abou-Seri, S.M. Synthesis and bioactivity evaluation of new 6-aryl-5-cyano thiouracils as potential antimicrobial and anticancer agents. Molecules, 2012, 17(8), 9868-9886. doi: 10.3390/molecules17089868 PMID: 22902882
  55. Mirmortazavi, S.S.; Farvandi, M.; Ghafouri, H.; Mohammadi, A.; Shourian, M. Evaluation of novel pyrimidine derivatives as a new class of mushroom tyrosinase inhibitor. Drug Des. Devel. Ther., 2019, 13, 2169-2178. doi: 10.2147/DDDT.S209324 PMID: 31371919
  56. Ghodasara, H.B.; Trivedi, A.R.; Kataria, V.B.; Patel, B.G.; Shah, V.H. Synthesis and antimicrobial evaluation of novel substituted pyrimidine scaffold. Med. Chem. Res., 2013, 22(12), 6121-6128. doi: 10.1007/s00044-013-0596-2
  57. Bakavoli, M.; Rahimizadeh, M.; Shiri, A.; Akbarzadeh, M.; Mousavi, S.H.; Atapour-Mashhad, H.; Tayarani-Najaran, Z. Synthesis and Anticancer Evaluation of New Derivatives of 3-Phenyl-1,5-Dimethyl-1H-1,2,4Triazolo4′,3′:1,2Pyrimido4,5-e 1,3,4Oxadiazine. J. Chem. Res., 2010, 34(7), 403-406. doi: 10.3184/030823410X520778
  58. Bakavoli, M.; Rahimizadeh, M.; Shiri, A.; Akbarzadeh, M.; Mousavi, S.H.; Tayarani-Najaran, Z.; Atapour-Mashhad, H.; Nikpour, M. Synthesis of new derivatives of 3‐aryl‐1,5‐dimethyl‐1H‐1,2,4triazolo4′,3′:1,2pyrimido4,5‐e1,3,4oxadiazines as potential antiproliferative agents. J. Heterocycl. Chem., 2011, 48(1), 183-187. doi: 10.1002/jhet.509
  59. Mousavi, S.H.; Atapour-Mashhad, H.; Bakavoli, M.; Shiri, A.; Akbarzadeh, M.; Tayarani-Najaran, Z. Pyrimidooxadiazine and triazolopyrimidooxadiazine derivatives: Synthesis and cytotoxic evaluation in human cancer cell lines. Bioorg. Khim., 2015, 41(2), 227-234. doi: 10.7868/S0132342315020074 PMID: 26165130
  60. Atapour-Mashhad, H.; Soukhtanloo, M.; Massoudi, A.; Shiri, A.; Parizadeh, S.M.; Bakavoli, M. Synthesis and antiproliferative evaluation of new pyrimido1,6‐athieno2,3‐dpyrimidine derivatives. J. Heterocycl. Chem., 2017, 54(1), 366-374. doi: 10.1002/jhet.2592
  61. Diveshkumar, K.V.; Sakrikar, S.; Harikrishna, S.; Dhamodharan, V.; Pradeepkumar, P.I. Targeting promoter G-quadruplex DNAs by indenopyrimidine-based ligands. ChemMedChem, 2014, 9(12), 2754-2765. doi: 10.1002/cmdc.201402394 PMID: 25359695
  62. Bhuma, N.; Chand, K.; Andréasson, M.; Mason, J.; Das, R.N.; Patel, A.K.; Öhlund, D.; Chorell, E. The effect of side chain variations on quinazoline-pyrimidine G-quadruplex DNA ligands. Eur. J. Med. Chem., 2023, 248, 115103. doi: 10.1016/j.ejmech.2023.115103 PMID: 36645982
  63. Ferreira, R; Aviñó, A; Pérez-Tomás, R; Gargallo, R; Eritja, R Synthesis and g-quadruplex-binding properties of defined acridine oligomers. J. Nucleic Acids, 2010, 2010 doi: 10.4061/2010/489060
  64. Sochacka-Ćwikła, A.; Regiec, A.; Zimecki, M.; Artym, J.; Zaczyńska, E.; Kocięba, M.; Kochanowska, I.; Bryndal, I.; Pyra, A.; Mączyński, M. Synthesis and biological activity of new 7-amino-oxazolo 5, 4-d pyrimidine derivatives. Molecules, 2020, 25(15), 3558. doi: 10.3390/molecules25153558 PMID: 32759841
  65. Barril, P.; Nates, S. Introduction to agarose and polyacrylamide gel electrophoresis matrices with respect to their detection sensitivities. In: Gel Electrophoresis - Principles and Basics; , 2012; pp. 3-14. doi: 10.5772/38573
  66. Wang, Y.; Patel, D.J. Solution structure of the human telomeric repeat dAG3(T2AG3)3 G-tetraplex. Structure, 1993, 1(4), 263-282. doi: 10.1016/0969-2126(93)90015-9 PMID: 8081740
  67. Lu, Q.; Liu, W.; Ding, J.; Cai, J.; Duan, W. Shikonin derivatives: Synthesis and inhibition of human telomerase. Bioorg. Med. Chem. Lett., 2002, 12(10), 1375-1378. doi: 10.1016/S0960-894X(02)00158-0 PMID: 11992780
  68. Rosu, F.; Gabelica, V.; De Pauw, E.; Antoine, R.; Broyer, M.; Dugourd, P. UV spectroscopy of DNA duplex and quadruplex structures in the gas phase. J. Phys. Chem. A, 2012, 116(22), 5383-5391. doi: 10.1021/jp302468x PMID: 22568521
  69. Magdeldin, S. Gel Electrophoresis: Principles and Basics; BoD–Books on Demand, 2012, p. 378.
  70. Di Somma, S.; Amato, J.; Iaccarino, N.; Pagano, B.; Randazzo, A.; Portella, G.; Malfitano, A.M. G-quadruplex binders induce immunogenic cell death markers in aggressive breast cancer cells. Cancers (Basel), 2019, 11(11), 1797. doi: 10.3390/cancers11111797 PMID: 31731707
  71. Haldar, S.; Zhang, Y.; Xia, Y.; Islam, B.; Liu, S.; Gervasio, F.L.; Mulholland, A.J.; Waller, Z.A.E.; Wei, D.; Haider, S. Mechanistic Insights into the Ligand-Induced Unfolding of an RNA G-Quadruplex. J. Am. Chem. Soc., 2022, 144(2), 935-950. doi: 10.1021/jacs.1c11248 PMID: 34989224
  72. O’Hagan, M.P.; Haldar, S.; Morales, J.C.; Mulholland, A.J.; Galan, M.C. Enhanced sampling molecular dynamics simulations correctly predict the diverse activities of a series of stiff-stilbene G-quadruplex DNA ligands. Chem. Sci. (Camb.), 2021, 12(4), 1415-1426. doi: 10.1039/D0SC05223J PMID: 34163904
  73. Ortiz de Luzuriaga, I.; Lopez, X.; Gil, A. Learning to model G-quadruplexes: Current methods and perspectives. Annu. Rev. Biophys., 2021, 50(1), 209-243. doi: 10.1146/annurev-biophys-060320-091827 PMID: 33561349
  74. Bakavoli, M.; Rahimizadeh, M. New access to thiazolo 4, 5-d pyrimidine derivatives. J. Heterocycl. Chem., 2006, 43.
  75. Mousavi, S.H.; Tavakkol-Afshari, J.; Brook, A.; Jafari-Anarkooli, I. Role of caspases and Bax protein in saffron-induced apoptosis in MCF-7 cells. Food Chem. Toxicol., 2009, 47(8), 1909-1913. doi: 10.1016/j.fct.2009.05.017 PMID: 19457443
  76. Mousavi, S.H.; Tavakkol-Afshari, J.; Brook, A.; Jafari-Anarkooli, I. Direct toxicity of Rose Bengal in MCF-7 cell line: Role of apoptosis. Food Chem. Toxicol., 2009, 47(4), 855-859. doi: 10.1016/j.fct.2009.01.018 PMID: 19271285
  77. Forouzanfar, F.; Mousavi, S.H. Targeting autophagic pathways by plant natural compounds in cancer treatment. Curr. Drug Targets, 2020, 21(12), 1237-1249. doi: 10.2174/1389450121666200504072635 PMID: 32364070
  78. de Bruijn, H.S.; Brooks, S.; van der Ploeg-van den Heuvel, A.; ten Hagen, T.L.M.; de Haas, E.R.M.; Robinson, D.J. Light fractionation significantly increases the efficacy of photodynamic therapy using BF-200 ALA in normal mouse skin. PLoS One, 2016, 11(2), e0148850. doi: 10.1371/journal.pone.0148850 PMID: 26872051
  79. Sitzmann, M.; Weidlich, I.E.; Filippov, I.V.; Liao, C.; Peach, M.L.; Ihlenfeldt, W.D.; Karki, R.G.; Borodina, Y.V.; Cachau, R.E.; Nicklaus, M.C. PDB ligand conformational energies calculated quantum-mechanically. J. Chem. Inf. Model., 2012, 52(3), 739-756. doi: 10.1021/ci200595n PMID: 22303903
  80. Liao, Q.H.; Gao, Q.Z.; Wei, J.; Chou, K.C. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Med. Chem., 2011, 7(1), 24-31.
  81. Lewis, E.A.; Munde, M.; Wang, S.; Rettig, M.; Le, V.; Machha, V.; Wilson, W.D. Complexity in the binding of minor groove agents: netropsin has two thermodynamically different DNA binding modes at a single site. Nucleic Acids Res., 2011, 39(22), 9649-9658. doi: 10.1093/nar/gkr699 PMID: 21890907
  82. Atapour-Mashhad, H.; Soukhtanloo, M.; Massoudi, A.; Shiri, A.; Bakavoli, M. Synthesis and evaluation of cytotoxicity of 6-amino-4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitriles. Russ. J. Bioorganic Chem., 2016, 42(3), 316-322. doi: 10.1134/S1068162016020047
  83. Parkinson, G.N.; Lee, M.P.H.; Neidle, S. Crystal structure of parallel quadruplexes from human telomeric DNA. Nature, 2002, 417(6891), 876-880. doi: 10.1038/nature755 PMID: 12050675
  84. Spiegel, J.; Adhikari, S.; Balasubramanian, S. The structure and function of DNA G-quadruplexes. Trends Chem., 2020, 2(2), 123-136. doi: 10.1016/j.trechm.2019.07.002 PMID: 32923997
  85. Huppert, J.L. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem. Soc. Rev., 2008, 37(7), 1375-1384. doi: 10.1039/b702491f PMID: 18568163
  86. Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J.H.; Ohyashiki, K. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene, 2006, 25(42), 5719-5725. doi: 10.1038/sj.onc.1209577 PMID: 16652154
  87. Hampel, S.M.; Sidibe, A.; Gunaratnam, M.; Riou, J.F.; Neidle, S. Tetrasubstituted naphthalene diimide ligands with selectivity for telomeric G-quadruplexes and cancer cells. Bioorg. Med. Chem. Lett., 2010, 20(22), 6459-6463. doi: 10.1016/j.bmcl.2010.09.066 PMID: 20932753
  88. Kelland, L.R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics – current status and future prospects. Eur. J. Cancer, 2005, 41(7), 971-979. doi: 10.1016/j.ejca.2004.11.024 PMID: 15862745
  89. Xiong, Y.X.; Huang, Z.S.; Tan, J.H. Targeting G-quadruplex nucleic acids with heterocyclic alkaloids and their derivatives. Eur. J. Med. Chem., 2015, 97, 538-551. doi: 10.1016/j.ejmech.2014.11.021 PMID: 25466923
  90. Mitteaux, J.; Lejault, P.; Wojciechowski, F.; Joubert, A.; Boudon, J. Identifying G-quadruplex-DNA-disrupting small molecules. J. Antican. Chem. Soc., 2021, 143(32), 12567-12577.
  91. Olejko, L.; Dutta, A.; Shahsavar, K.; Bald, I. Influence of different salts on the G-quadruplex structure formed from the reversed human telomeric DNA sequence. Int. J. Mol. Sci., 2022, 23(20), 12206. doi: 10.3390/ijms232012206 PMID: 36293060
  92. Kaneta, T.; Ogura, T.; Yamato, S.; Imasaka, T. Band broadening of DNA fragments isolated by polyacrylamide gel electrophoresis in capillary electrophoresis. J. Sep. Sci., 2012, 35(3), 431-435. doi: 10.1002/jssc.201100909 PMID: 22258810
  93. Rao, Y.; Xiong, W.; Liu, H.; Jia, C.; Zhang, H.; Cui, Z.; Zhang, Y.; Cui, J. Inhibition of telomerase activity by dominant-negative hTERT retards the growth of breast cancer cells. Breast Cancer, 2016, 23(2), 216-223. doi: 10.1007/s12282-014-0553-z PMID: 25098685
  94. Baykal, A.; Rosen, D.; Zhou, C.; Liu, J.; Sahin, A.A. Telomerase in breast cancer: A critical evaluation. Adv. Anat. Pathol., 2004, 11(5), 262-268. doi: 10.1097/01.pap.0000138145.19258.64 PMID: 15322492
  95. Dalle Carbonare, L.; Valenti, M.T.; Azzarello, G.; Balducci, E.; Crepaldi, G.; Realdi, G.; Vinante, O.; Giannini, S. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol. Cell. Endocrinol., 2005, 240(1-2), 23-31. doi: 10.1016/j.mce.2005.03.018 PMID: 15978718
  96. Woo, H.J.; Lee, S.J.; Choi, B.T.; Park, Y.M.; Choi, Y.H. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp. Mol. Pathol., 2007, 82(1), 77-84. doi: 10.1016/j.yexmp.2006.02.004 PMID: 16574101
  97. Salimi-Jeda, A.; Badrzadeh, F.; Esghaei, M.; Abdoli, A. The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches. Cancer Treat. Res. Commun., 2021, 27, 100323. doi: 10.1016/j.ctarc.2021.100323 PMID: 33530025
  98. Sun, Y.; Yang, Y.; Shen, H.; Huang, M.; Wang, Z.; Liu, Y.; Zhang, H.; Tang, T.S.; Guo, C. iTRAQ-based chromatin proteomic screen reveals CHD4-dependent recruitment of MBD2 to sites of DNA damage. Biochem. Biophys. Res. Commun., 2016, 471(1), 142-148. doi: 10.1016/j.bbrc.2016.01.162 PMID: 26827827
  99. Zhu, Z.; Tran, H.; Mathahs, M.M.; Fink, B.D.; Albert, J.A.; Moninger, T.O.; Meier, J.L.; Li, M.; Schmidt, W.N. Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity. Pharmacol. Res. Perspect., 2021, 9(6), e00882. doi: 10.1002/prp2.882 PMID: 34747573

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers